enGene Holdings Inc.·4

Feb 3, 4:10 PM ET

Daws D. Ryan 4

4 · enGene Holdings Inc. · Filed Feb 3, 2026

Research Summary

AI-generated summary of this filing

Updated

enGene (ENGN) CFO Daws D. Ryan Receives 220,000 Option Award

What Happened

  • Daws D. Ryan, Chief Financial Officer of enGene Holdings Inc. (ENGN), received a derivative award covering 220,000 shares on January 30, 2026. The Form 4 reports the acquisition price as $0.00, indicating this was a compensation grant (option award), not an open‑market purchase or sale.

Key Details

  • Transaction date: 2026-01-30; Form 4 filed 2026-02-03 (timely within the 2-business-day rule).
  • Transaction type/code: Award/other acquisition (A) — derivative instrument reported.
  • Shares/options granted: 220,000 (reported acquisition amount); reported price $0.00.
  • Vesting: This option vests monthly in substantially equal amounts over 48 months, subject to continued service (footnote).
  • Shares owned after transaction: Not specified in the provided filing excerpt.
  • Not a sale or purchase of shares on the open market; no immediate cash changed hands.

Context

  • This is a standard executive compensation grant (an option award) intended to incent ongoing service; vesting spreads the economic benefit over four years.
  • Such grants are routine and do not by themselves indicate insider buying or selling sentiment.

Insider Transaction Report

Form 4
Period: 2026-01-30
Daws D. Ryan
Chief Financial Officer
Transactions
  • Award

    Stock Option (Right to Buy)

    [F1]
    2026-01-30+220,000220,000 total
    Exercise: $9.53Exp: 2036-01-30Common Shares (220,000 underlying)
Footnotes (1)
  • [F1]This option vests monthly in substantially equal amounts for 48 months, subject to the reporting person's continued service.
Signature
/s/ D. Ryan Daws|2026-02-03

Documents

1 file
  • 4
    form4.xmlPrimary